麻豆传媒

Weijing Sun, MD, FACP, is a Director of Division of Medical Oncology in University of Kansas School of Medicine, and an Associate Director of University of Kansas Cancer Center. He specializes in the treatment of colorectal cancer.

Dr. Sun is board-certified in internal medicine and medical oncology. He received his medical degree from Shanghai Medical College, Fudan University, in Shanghai. He completed his residency in internal medicine at Loyola University Medical Center in Maywood, Ill., and his hematology-oncology fellowship at the University of Pennsylvania in Philadelphia.

Dr. Sun is a member of the American Medical Association, the American Society of Clinical Oncology, the American Association of Cancer Research, the Eastern Cooperative Group of Oncology Gastrointestinal Cancer Core Committee, the American College of Physicians 鈥� Internal Medicine, the NCI Gastrointestinal Cancer Steering Committee Hepatobiliary Task Force, and serves on the American Society of Clinical Oncology Scientific Program and Membership Committee. In addition, Dr. Sun has been recognized on U.S. 麻豆传媒 & World Report鈥檚 American Top Doctors list.

Steven K. Libutti, MD, FACS, was appointed as Director of Rutgers Cancer Institute of New Jersey and Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences in January 2017. In addition to his leadership roles within Rutgers University, Dr. Libutti also serves as Senior Vice President of Oncology Services for RWJBarnabas Health, further strengthening the university鈥檚 partnership with the healthcare system. He is also a Professor of Surgery at Rutgers Robert Wood Johnson Medical School and an Affiliated Distinguished Professor in Genetics at the Rutgers School of Arts and Sciences Department of Genetics.

Most recently, Dr. Libutti served as Director for the Montefiore Einstein Center for Cancer Care in New York City and was a Professor and Vice Chairman of the Department of Surgery and Professor in the Department of Genetics at Albert Einstein College of Medicine and Montefiore Health System. A surgical oncologist, Dr. Libutti is an internationally known expert in endocrine surgery and the management of neuroendocrine tumors. He is the immediate Past President of the American Association of Endocrine Surgeons. His clinical practice focuses on gastrointestinal malignancies including cancers of the liver and pancreas.

The recipient of funding from the National Cancer Institute (NCI) for the past 20 years, Dr. Libutti is also a researcher whose work focuses on developing novel cancer therapies through an understanding of the tumor microenvironment and blood vessel formation in tumors. He is studying tumor neovascular formation and the interaction between tumor cells, endothelial cells and the components of the tumor microenvironment including fibroblasts and cancer stem cells. His work also focuses on a better understanding of the tumor suppressor genes MEN1 and FILIP1L.

After graduating magna cum laude from Harvard College, Dr. Libutti received his medical degree from the College of Physicians and Surgeons of Columbia University. He remained at Presbyterian Hospital in New York where he completed his residency in surgery, followed by a fellowship at the NCI in surgical oncology and endocrine surgery. He continued at the NCI where he became a tenured Senior Investigator and Chief of the Tumor Angiogenesis Section in the Surgery Branch.  He has published over 280 peer reviewed journal articles, is Editor-in-Chief of the Nature Journal Cancer Gene Therapy, and holds seven U.S. patents. 

Clinical Expertise:
Neuroendocrine tumors, thyroid cancer, parathyroid tumors, pancreatic cancer, liver cancer, gastrointestinal (GI) cancers, minimally invasive surgery, and clinical trials.

Paul J. Thuluvath, M.D., Chief, Division of Gastroenterology at Mercy Medical Center, and Medical Director for The Melissa L. Posner Institute for Digestive Health & Liver Disease at Mercy leads a top rated physician team of gastroenterology specialists in Baltimore, Maryland, who help patients find the best treatment options for digestive diseases and liver conditions. As the leader of The Center for Liver and Hepatobiliary Diseases, Dr. Paul Thuluvath provides patients with pioneering treatments and advanced technology to help them manage their illness. He is a recognized national and international authority in liver and biliary diseases and dedicated to medical research and clinical trials that are advancing treatment possibilities for patients. While his patients respect his expertise, they value his bedside concern, empathy and personal care that keeps them encouraged. He welcomes patient questions and family involvement, and is devoted to patient education in the healing process. Dr. Thuluvath and his team of gastroenterology specialists provide expertise, comprehensive care, advanced facilities for endoscopy procedures and leading edge technology, treatment and pioneering medical research. Dr. Paul Thuluvath coordinates patient care, when needed, working in collaboration with the specialists of The Institute for Cancer Care at Mercy, The Center for Minimally Invasive Surgery at Mercy, The Center for Interventional Pain Medicine at Mercy, The Lung Center at Mercy, and the Division of Interventional Radiology. This comprehensive approach to diagnosis and treatment of digestive health and liver disease and the expertise of our doctors makes The Institute for Digestive Health and Liver Disease at Mercy a leader in the Mid-Atlantic region. Authority in Liver and Biliary Diseases Dr. Paul Thuluvath is a known authority in liver and biliary diseases and pre-and post-liver transplant management. He serves on the Editorial Board for: Hepatology, Liver Transplant, and Gastrointestinal Endoscopy. He is a frequent speaker and lecturer at national and international meetings on issues in liver and biliary diseases and has addressed medical groups in China, Germany, India, London, Oman, Philippines, Singapore and the United States.

Nigel Girgrah, MD, is chief wellness officer at Ochsner Health in New Orleans. He leads the Office of Professional Well-Being, which is charged with improving the professional fulfillment of Ochsner physicians and staff. The office focuses on enhanced practice efficiency, as well as personal and team resilience, and building an organizational culture that promotes provider well-being. He has given numerous media on the subject.
Dr. Girgrah received both his medical degree and Ph.D. from the University of Toronto. He has specialist certification in both gastroenterology and internal medicine with the Royal College of Physicians and Surgeons of Canada. He is a practicing transplant hepatologist and serves as Ochsner's medical director of liver transplantation.
 

Steven K. Libutti, MD, FACS was appointed Director of Rutgers Cancer Institute and Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences in January 2017. On October 17th, 2024, Dr. Libutti was named the inaugural William N. Hait Director of Rutgers Cancer Institute. In addition to his leadership roles within Rutgers University, Dr. Libutti serves as Senior Vice President of Oncology Services for RWJBarnabas Health. He is also a Distinguished Professor of Surgery at Rutgers Robert Wood Johnson Medical School and an Affiliated Distinguished Professor in Genetics, Rutgers School of Arts and Sciences. 
 
After graduating magna cum laude from Harvard College, Dr. Libutti received his medical degree from the College of Physicians and Surgeons of Columbia University. He remained at Presbyterian Hospital in New York where he completed his residency in surgery, followed by a fellowship at the National Cancer Institute (NCI) in surgical oncology. He continued at the NCI where he became a tenured Senior Investigator and Chief of the Tumor Angiogenesis Section in the Surgery Branch. Following his time at the NCI, he served as the Director of the Montefiore Einstein Center for Cancer Care and as an Associate Director of the Albert Einstein Cancer Center for eight years prior to joining Rutgers and RWJBarnabas Health.
 
Dr. Libutti is an internationally known expert in the management of neuroendocrine tumors and Past President of the American Association of Endocrine Surgeons. His clinical practice focuses on gastrointestinal malignancies including cancers of the liver and pancreas. The recipient of funding from the NCI for the past 25 years, Dr. Libutti is also a researcher whose work focuses on developing novel cancer therapies through an understanding of the tumor microenvironment as well as on a better understanding of the tumor suppressor genes MEN1 and FILIP1L. He has published over 300 peer reviewed journal articles, is Editor-in-Chief Emeritus of the Springer-Nature Journal Cancer Gene Therapy and holds eleven U.S. patents. Dr. Libutti has successfully navigated Rutgers Cancer Institute’s P30 CCSG Comprehensive Cancer Center Award through two competitive renewals, the most recent of which in 2023 achieved the Center’s highest score to date placing it among the top centers in the US.